Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chad Reder

Ophthalmology Fresno, CA Medical Doctor

NPI 1336138924 CMS profile 151203

1680 E Herndon Ave, Ste 101, Fresno, CA 93720

Open in the dashboard

General payments

$4,872

227 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chad Reder of Fresno, CA is reported in the CMS Open Payments database as having received $4,872 across 227 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $719 11
2021 General $1,238 71
2020 General $861 62
2019 General $2,055 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chad Reder
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Chad Reder were reported at $719. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Chad Reder Ophthalmology median Middle half National median
2019 $2,055 $258 $104–$655 $163
2020 $861 $126 $45–$321 $114
2021 $1,238 $205 $76–$534 $132
2022 $0 $266 $100–$678 $149
2023 $0 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $719 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb, a division of Bausch Health US, LLC $1,256 105 payments
  2. Glaukos Corporation $786 14 payments
  3. Alcon Vision LLC $734 22 payments
  4. TissueTech, Inc. $558 17 payments
  5. Omeros Corporation $504 32 payments
  6. Novartis Pharmaceuticals Corporation $244 5 payments
  7. Tarsus Pharmaceuticals, Inc. $113 1 payment
  8. Johnson & Johnson Surgical Vision, Inc. $105 6 payments
  9. Aerie Pharmaceuticals, Inc. $98 2 payments
  10. Ocular Therapeutix, Inc. $97 5 payments
  11. Other $377 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,853 226 payments
  2. Gift $19 1 payment
Products named General payments · program years 2019–2025
  1. Omidria $504 32 payments
  2. LOTEMAX SM $467 41 payments
  3. iStent inject Trabecular Micro-Bypass Stent System $437 9 payments
  4. PROKERA $414 9 payments
  5. AMNIOGRAFT $414 9 payments
  6. BESIVANCE $304 36 payments
  7. ReSTOR $273 6 payments
  8. iDoseTR $263 2 payments
  9. VYZULTA $206 10 payments
  10. LenSx $146 2 payments
  11. Other $2,227 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record